Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Enbrel manufacturer speaks of post-approval plan
Washington, D.C. Officials of Amgen spoke of teaching patientsabout biologic treatments of psoriasis, dermatologists spreading the wordabout the new class of drugs, and the physician-patient relationship asits Enbrel (etanercept) added to the resume leading it toward approval bythe U.S. Food and Drug Administration.
Recent Videos
Related Content
